BioLine Rx (BLRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BLRX BioLine Rx

Watchlist

0.612
+0.036+6.31%

Close Apr 26 16:00 ET

0.620
+0.008+1.37%

Post 17:51 ET

48.89MMarket Cap-679P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
TipRanksApr 17 11:05 ET
Express News | BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
Moomoo 24/7Apr 17 07:02 ET
Express News | BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
Moomoo 24/7Apr 10 07:14 ET
Express News | BioLineRx Shares Are Trading Lower After the Company Announced a $6 Million Registered Direct Offering
Moomoo 24/7Apr 1 14:28 ET
BioLineRx to Raise $6M Through a Direct Offering
Seeking AlphaApr 1 09:14 ET
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced t
BenzingaApr 1 09:02 ET

Comments

Trytosaveabit

Apr 10 19:15

Update

$BioLine Rx(BLRX.US)$ BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock

Trytosaveabit

Mar 4 20:10

$BioLine Rx(BLRX.US)$ BioLineRx Announces Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production, New Patent, When Issued, Will Be Valid Until December 2041

Stock Region

Mar 1 23:28

Renowned Investment Bank Reiterates Buy Rating For Israeli Medical Company

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target: A Deep Dive into the Potential of $BLRX.
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's futur...